A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures

By Kalviainen R.   Brodie M.J.   Duncan J.   Chadwick D.   Edwards D.   Lyby K.   for the Northern European Tiagabine Study Group  

Epilepsy Research, Vol. 30, Iss. 1, 1998-03 ,pp. : 31-40

Elsevier

Access to resources Recommend Favorite

Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood

By Dodrill C.B.   Arnett J.L.   Deaton R.   Lenz G.T.   Sommerville K.W.  

Epilepsy Research, Vol. 42, Iss. 2, 2000-12 ,pp. : 123-132

Elsevier

Access to resources Recommend Favorite

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

By Grant R.   Shorvon S.D.  

Epilepsy Research, Vol. 42, Iss. 2, 2000-12 ,pp. : 89-95

Elsevier

Access to resources Recommend Favorite

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

By Ben-Menachem E.   Edrich P.   Van Vleymen B.   Sander J.W.A.S.   Schmidt B.  

Epilepsy Research, Vol. 53, Iss. 1, 2003-02 ,pp. : 57-64

Elsevier

Access to resources Recommend Favorite

The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome

By Siegel H.   Kelley K.   Stertz B.   Reeves-Tyer P.   Flamini R.   Malow B.   Gaillard W.D.   Ko D.   Theodore W.H.  

Epilepsy Research, Vol. 34, Iss. 2, 1999-04 ,pp. : 91-97

Elsevier

Access to resources Recommend Favorite